Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Michelle Luo"'
Autor:
Amber Morey, Martin Ng, Michail Spanos, Piyan Zhang, Tuoye Xu, Willi Cheung, Emeli Chatterjee, Priyanka Gokulnath, Natacha Carnel-Amar, Ana Luisa Soares Chiaretti, Collin Nelson, Jubin George, Michelle Luo, Abhik Chakraborty, Luiza Perucci, Jennifer C. Jones, Peter De Hoff, Jeffrey L. Franklin, Robert L. Raffai, Saumya Das, David A. Routenberg, John P. Nolan, Al Charest, Louise C. Laurent, Roger P. Alexander
Publikováno v:
Extracellular Vesicle, Vol 3, Iss , Pp 100040- (2024)
Antibodies are critical tools for research into extracellular vesicles (EVs) and other extracellular nanoparticles (ENPs), where they can be used for their identification, characterization, and isolation. However, the lack of a centralized antibody p
Externí odkaz:
https://doaj.org/article/c574ad4817ab4125884807ebdd8ff9a1
Publikováno v:
JMIR Formative Research, Vol 8, p e52251 (2024)
BackgroundCyclic vomiting syndrome (CVS) is an enigmatic and debilitating disorder of gut-brain interaction that is characterized by recurrent episodes of severe vomiting and nausea. It significantly impairs patients’ quality of life and can lead t
Externí odkaz:
https://doaj.org/article/cd843abcab074c2992fd042c76700437
Autor:
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas deLaat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Publikováno v:
Molecular Oncology, Vol 18, Iss 1, Pp 113-135 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. However, the potential contribution of the primary fibrinolytic protease plasminogen to PDAC d
Externí odkaz:
https://doaj.org/article/d7e6f70905c245e1a019d7d8c2f2e56f
Autor:
Thomas M Herndon, Cristina Ausin, Nina N Brahme, Sarah J Schrieber, Michelle Luo, Frances C Andrada, Carol Kim, Wanjie Sun, Lingjie Zhou, Stella Grosser, Sarah Yim, M Stacey Ricci
Publikováno v:
PLoS ONE, Vol 18, Iss 10, p e0292231 (2023)
Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic. Randomized controlled studies and e
Externí odkaz:
https://doaj.org/article/0f459bb1654048f39c0ff91ad7b48459
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 12 (2019)
Background: Irritable bowel syndrome (IBS) reduces quality of life and burdens healthcare systems. This study identified factors associated with frequent use of IBS diagnostic tests and procedures. Methods: Using a United States claims database (2001
Externí odkaz:
https://doaj.org/article/83af8acce8ab48a59413d0480adcec56
Publikováno v:
Crohn's & Colitis 360. 4
Background A previously developed clinical decision support tool (CDST) identified patients with Crohn’s disease (CD) most likely to respond to vedolizumab. This study evaluated the ability of the CDST to predict real-world healthcare resource util
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d24588486c69366231a9f26e2cd3f38c
https://doi.org/10.1093/crocol/otac048
https://doi.org/10.1093/crocol/otac048
Autor:
Karen Lasch, Blair Fennimore, Frank I. Scott, James D. Lewis, Ronac Mamtani, Mark E. Gerich, Yash Shah, Ravy K. Vajravelu, Michelle Luo
Publikováno v:
J Crohns Colitis
Background and Aims There are limited data on the most cost-effective sequencing of biologics for ulcerative colitis [UC]. Methods We used Markov modelling to identify the most cost-effective position for vedolizumab among biologics for steroid-depen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5eeeee0d23111321c692677d030248f
https://pubmed.ncbi.nlm.nih.gov/31901085
https://pubmed.ncbi.nlm.nih.gov/31901085
Autor:
Monika Fischer, Arun Swaminath, Joseph Meserve, Khadija Chaudrey, Nitin Gupta, David Faleck, Corey A. Siegel, Eugenia Shmidt, Dana J. Lukin, William J. Sandborn, Bo Shen, Niels Vande Casteele, Matthew Bohm, Michelle Luo, Gursimran Kochhar, Jenna L. Koliani-Pace, David Hudesman, Siddharth Singh, Edward V. Loftus, Sunanda V. Kane, Keith Sultan, Shannon Chang, Robert Hirten, Parambir S. Dulai, Justin Hartke, Jean-Frederic Colombel, Karen Lasch, Morris Barocas, Brigid S. Boland, Sashidhar Sagi, Prianka Chilukuri, Bruce E. Sands
Publikováno v:
Inflammatory Bowel Diseases. 24:2461-2467
Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) of a prospectively maintain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7bf71d58fdc07d832d4e140e7a270f8
https://doi.org/10.1093/ibd/izy171
https://doi.org/10.1093/ibd/izy171
Autor:
Gerassimos J. Mantzaris, E Billmyer, H Nguyen, Shashi Adsul, Michelle Luo, S Wang, Andres Yarur, Brian Bressler, P Kamble, A Guerin
Publikováno v:
Journal of Crohn's and Colitis. 15:S095-S096
Background Previously, we identified subsets of biologic-naïve patients (pts) with Crohn’s disease (CD) from the EVOLVE study who had higher rates of clinical remission (CR) [Fig 1] when initiating vedolizumab (VDZ) vs anti-TNFα treatment, using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc6fd81abe691f0bb9cb63ad2da1172f
https://doi.org/10.1093/ecco-jcc/jjab073.099
https://doi.org/10.1093/ecco-jcc/jjab073.099
Autor:
Pravin Kamble, K. Elomaa, Peter Szolovits, Irene Y. Chen, Willie Boag, H.M. Berlin, S. Wang, Michelle Luo, David Sontag
Publikováno v:
Value in Health. 24:S99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de315c5d57c6cc4293c52eb8c25bdf19
https://doi.org/10.1016/j.jval.2021.04.516
https://doi.org/10.1016/j.jval.2021.04.516